These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 9815822

  • 1. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.
    Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, Balk SP.
    Clin Cancer Res; 1997 Aug; 3(8):1383-8. PubMed ID: 9815822
    [Abstract] [Full Text] [Related]

  • 2. Suppression of mutant androgen receptors by flutamide.
    Ishioka J, Hara S, Isaacs JT, Tomura A, Nishikawa K, Kageyama Y.
    Int J Urol; 2009 May; 16(5):516-21. PubMed ID: 19389135
    [Abstract] [Full Text] [Related]

  • 3. Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone.
    Culig Z, Stober J, Gast A, Peterziel H, Hobisch A, Radmayr C, Hittmair A, Bartsch G, Cato AC, Klocker H.
    Cancer Detect Prev; 1996 May; 20(1):68-75. PubMed ID: 8907206
    [Abstract] [Full Text] [Related]

  • 4. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
    Andrieu T, Bertolini R, Nichols SE, Setoud R, Frey FJ, Baker ME, Frey BM.
    Biochem Pharmacol; 2011 Dec 01; 82(11):1651-62. PubMed ID: 21907706
    [Abstract] [Full Text] [Related]

  • 5. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
    Urushibara M, Ishioka J, Hyochi N, Kihara K, Hara S, Singh P, Isaacs JT, Kageyama Y.
    Prostate; 2007 Jun 01; 67(8):799-807. PubMed ID: 17373727
    [Abstract] [Full Text] [Related]

  • 6. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
    Zhang M, Latham DE, Delaney MA, Chakravarti A.
    Oncogene; 2005 Apr 07; 24(15):2474-82. PubMed ID: 15735703
    [Abstract] [Full Text] [Related]

  • 7. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
    Ozers MS, Marks BD, Gowda K, Kupcho KR, Ervin KM, De Rosier T, Qadir N, Eliason HC, Riddle SM, Shekhani MS.
    Biochemistry; 2007 Jan 23; 46(3):683-95. PubMed ID: 17223690
    [Abstract] [Full Text] [Related]

  • 8. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
    Wang LG, Liu XM, Kreis W, Budman DR.
    Biochem Biophys Res Commun; 1999 May 27; 259(1):21-8. PubMed ID: 10334909
    [Abstract] [Full Text] [Related]

  • 9. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.
    Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS.
    Mol Endocrinol; 1997 Apr 27; 11(4):450-9. PubMed ID: 9092797
    [Abstract] [Full Text] [Related]

  • 10. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
    Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP.
    Cancer Res; 1999 Jun 01; 59(11):2511-5. PubMed ID: 10363963
    [Abstract] [Full Text] [Related]

  • 11. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
    Whitaker HC, Hanrahan S, Totty N, Gamble SC, Waxman J, Cato AC, Hurst HC, Bevan CL.
    Clin Cancer Res; 2004 Nov 01; 10(21):7392-401. PubMed ID: 15534116
    [Abstract] [Full Text] [Related]

  • 12. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
    Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M.
    Cancer Res; 2003 Jan 01; 63(1):149-53. PubMed ID: 12517791
    [Abstract] [Full Text] [Related]

  • 13. Antiandrogens prevent stable DNA-binding of the androgen receptor.
    Farla P, Hersmus R, Trapman J, Houtsmuller AB.
    J Cell Sci; 2005 Sep 15; 118(Pt 18):4187-98. PubMed ID: 16141232
    [Abstract] [Full Text] [Related]

  • 14. Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.
    Attardi BJ, Burgenson J, Hild SA, Reel JR.
    Mol Cell Endocrinol; 2004 Jul 30; 222(1-2):121-32. PubMed ID: 15249132
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.
    Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H.
    Mol Endocrinol; 1993 Dec 30; 7(12):1541-50. PubMed ID: 8145761
    [Abstract] [Full Text] [Related]

  • 18. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
    Zaia A, Fraizer GC, Piantanelli L, Saunders GF.
    Anticancer Res; 2001 Dec 30; 21(1A):1-10. PubMed ID: 11299720
    [Abstract] [Full Text] [Related]

  • 19. Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status.
    Wetherill YB, Fisher NL, Staubach A, Danielsen M, de Vere White RW, Knudsen KE.
    Cancer Res; 2005 Jan 01; 65(1):54-65. PubMed ID: 15665279
    [Abstract] [Full Text] [Related]

  • 20. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function.
    Buchanan G, Yang M, Harris JM, Nahm HS, Han G, Moore N, Bentel JM, Matusik RJ, Horsfall DJ, Marshall VR, Greenberg NM, Tilley WD.
    Mol Endocrinol; 2001 Jan 01; 15(1):46-56. PubMed ID: 11145738
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.